ABCL AbCellera Biologics Inc.

NASDAQ
$11.12

AbCellera Biologics Inc. (ABCL) is expected to report earnings on February 8, 2027, after the market close. The consensus earnings estimate is a loss of $0.18 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -9.3% since its last earnings release on November 9, 2026.

AbCellera Biologics Beat Consensus Estimates
Monday, November 9, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 8
Monday · 4:05 PM ET
Earnings Whisper
-
vs ($0.18)
Rev est $5.68M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $11.80

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About AbCellera Biologics Inc.

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.